Search Result

Results for "

cardiac markers

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) Aminotransferases (Transaminases) (4) Angiotensin-converting Enzyme (ACE) (1) Apoptosis (3) Biochemical Assay Reagents (1) Cathepsin (1) Cytochrome P450 (1) DNA/RNA Synthesis (2) G Protein-coupled Receptor Kinase (GRK) (2) HDAC (1) Indoleamine 2,3-Dioxygenase (IDO) (2) LDLR (2) Mitochondrial Metabolism (2) MMP (1) NF-κB (3) p38 MAPK (2) PI3K (2) PIN1 (1) Reactive Oxygen Species (ROS) (2) ROCK (2) TNF Receptor (1)
By Research Areas:	Cancer (4) Cardiovascular Disease (8) Inflammation/Immunology (4) Metabolic Disease (2) Neurological Disease (4)

By Targets:

Akt (2)

Aminotransferases (Transaminases) (4)

Angiotensin-converting Enzyme (ACE) (1)

Apoptosis (3)

Biochemical Assay Reagents (1)

Cathepsin (1)

Cytochrome P450 (1)

DNA/RNA Synthesis (2)

G Protein-coupled Receptor Kinase (GRK) (2)

HDAC (1)

Indoleamine 2,3-Dioxygenase (IDO) (2)

LDLR (2)

Mitochondrial Metabolism (2)

MMP (1)

NF-κB (3)

p38 MAPK (2)

PI3K (2)

PIN1 (1)

Reactive Oxygen Species (ROS) (2)

ROCK (2)

TNF Receptor (1)

By Research Areas:

Cancer (4)

Cardiovascular Disease (8)

Inflammation/Immunology (4)

Metabolic Disease (2)

Neurological Disease (4)

Inhibitors & Agonists

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16657

TAPI-1 Maximum Cited Publications 15 Publications Verification	MMP NF-κB Apoptosis TNF Receptor	Inflammation/Immunology Cancer
TAPI-1 is a broad-spectrum MMP inhibitor and NF-κB p65 inhibitor that targets ADAM17/TACE, ADAM10 and other proteins. TAPI-1 reduces the proteolytic cleavage of membrane-bound TNF-α, decreases TNF-α levels, inhibits NF-κB pathway activation, and downregulates profibrotic markers. TAPI-1 reduces the proportion of proinflammatory immune cells, alleviates cardiac and airway fibrosis, and improves cardiac function after myocardial infarction. Meanwhile, TAPI-1 inhibits the viability, migration and invasion of esophageal squamous cell carcinoma cells, enhances the chemosensitivity of Cisplatin (HY-17394), induces apoptosis, and shows low toxicity to normal esophageal epithelial cells. TAPI-1 can be widely used in studies related to myocardial infarction-induced heart failure, severe traumatic tracheal stenosis, esophageal squamous cell carcinoma and other conditions .

HY-P3016A

Aspartate aminotransferase, porcine heart EC 2.6.1.1, porcine heart; GOT, porcine heart; AST, porcine heart	Aminotransferases (Transaminases)	Cardiovascular Disease
Aspartate aminotransferase (EC 2.6.1.1), porcine heart is a metabolic regulator with the highest activity in the heart, liver and skeletal muscle. Aspartate aminotransferase, porcine heart comprises two isozymes: the cytoplasmic form (AST1) and the mitochondrial form (AST2). By catalyzing reversible transamination reactions between oxaloacetate, L-glutamate and other substances, it is deeply involved in key physiological processes such as amino acid metabolism, the tricarboxylic acid cycle and neurotransmitter synthesis. Aspartate aminotransferase, porcine heart also provides substrate support for the synthesis of urea and purines/pyrimidines. Aspartate aminotransferase, porcine heart is a serum marker reflecting cardiac and hepatic injury, and its abnormal levels are also closely associated with myocardial infarction, cardiovascular diseases and various cancers .

HY-N0430

Coptisine Coptisin	Indoleamine 2,3-Dioxygenase (IDO) NF-κB p38 MAPK PI3K Akt Apoptosis Reactive Oxygen Species (ROS) Mitochondrial Metabolism DNA/RNA Synthesis ROCK LDLR	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Coptisine is an orally active and brain-penetrant alkaloid found in Coptis chinensis. Coptisine is a reversible, uncompetitive IDO inhibitor with a K_i of 5.8 μM and an IC₅₀ of 6.3 μM. Coptisine suppresses neuroinflammation, reduces Aβ plaque burden and shows neuroprotective activity. Coptisine shows anti-inflammation activity by blocking NF-κB, MAPK, and PI3K/Akt activation. Coptisine inhibits cancer cells proliferation, induces DNA damage, G2/M phase cell cycle arrest, apoptosis, ROS production and mitochondrial dysfunction. Coptisine inhibits Rho/ROCK pathway activation, reduces arrhythmia, limits cardiac injury marker release, reduces infarct size, and preserves cardiac function in rat myocardial ischemia/reperfusion models. Coptisine downregulates HMGCR and upregulates LDLR and CYP7A1 to modulate cholesterol metabolism, reduces abnormal serum lipid levels, and promotes fecal bile acid excretion. Coptisine can be used for the research of cancer, hypercholesterolemia, Alzheimer’s disease, inflammatory disorders and cardiovascular disease .

HY-N0430A

Coptisine Sulfate 5 Publications Verification	Indoleamine 2,3-Dioxygenase (IDO) NF-κB p38 MAPK PI3K Akt Apoptosis Reactive Oxygen Species (ROS) Mitochondrial Metabolism DNA/RNA Synthesis ROCK LDLR	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Coptisine Sulfate is an orally active and brain-penetrant alkaloid found in Coptis chinensis. Coptisine Sulfate is a reversible, uncompetitive IDO inhibitor with a K_i of 5.8 μM and an IC₅₀ of 6.3 μM. Coptisine Sulfate suppresses neuroinflammation, reduces Aβ plaque burden and shows neuroprotective activity. Coptisine Sulfate shows anti-inflammation activity by blocking NF-κB, MAPK, and PI3K/Akt activation. Coptisine Sulfate inhibits cancer cells proliferation, induces DNA damage, G2/M phase cell cycle arrest, apoptosis, ROS production and mitochondrial dysfunction. Coptisine Sulfate inhibits Rho/ROCK pathway activation, reduces arrhythmia, limits cardiac injury marker release, reduces infarct size, and preserves cardiac function in rat myocardial ischemia/reperfusion models. Coptisine Sulfate downregulates HMGCR and upregulates LDLR and CYP7A1 to modulate cholesterol metabolism, reduces abnormal serum lipid levels, and promotes fecal bile acid excretion. Coptisine Sulfate be used for the research of cancer, hypercholesterolemia, Alzheimer’s disease, inflammatory disorders and cardiovascular disease .

HY-P3016

Aspartate aminotransferase, Genetically engineered bacteria EC 2.6.1.1; GOT; AST	Aminotransferases (Transaminases)	Cardiovascular Disease
Aspartate aminotransferase (EC 2.6.1.1), Genetically engineered bacteria is a metabolic regulator with the highest activity in the heart, liver and skeletal muscle. Aspartate aminotransferase, Genetically engineered bacteria comprises two isozymes: the cytoplasmic form (AST1) and the mitochondrial form (AST2). By catalyzing reversible transamination reactions between oxaloacetate, L-glutamate and other substances, it is deeply involved in key physiological processes such as amino acid metabolism, the tricarboxylic acid cycle and neurotransmitter synthesis. Aspartate aminotransferase, Genetically engineered bacteria also provides substrate support for the synthesis of urea and purines/pyrimidines. Aspartate aminotransferase, Genetically engineered bacteria is a serum marker reflecting cardiac and hepatic injury, and its abnormal levels are also closely associated with myocardial infarction, cardiovascular diseases and various cancers .

HY-P2632

RAD16-I RADA16	Biochemical Assay Reagents	Neurological Disease
RAD16-I (RADA16) is a non-directed self-assembling peptide hydrogel. Under physiological conditions, RAD16-I spontaneously forms a three-dimensional nanofiber network that mimics the extracellular matrix, and possesses excellent properties such as high water content, biocompatibility and degradability. RAD16-I serves as an ideal scaffold for three-dimensional cell culture. RAD16-I not only maintains cell viability and induces self-organization, but also supports cell adhesion, proliferation, differentiation and insulin secretion, effectively stabilizes islet clusters and promotes directed differentiation of the cardiac lineage. RAD16-I can construct a cell-friendly nano-microenvironment for research related to diseases such as myocardial infarction and diabetes .

HY-P3016B

Aspartate aminotransferase, Human liver EC 2.6.1.1, Human liver; GOT, Human liver; AST, Human liver	Aminotransferases (Transaminases)	Cardiovascular Disease
Aspartate aminotransferase (EC 2.6.1.1), Human liver is a metabolic regulator with the highest activity in the heart, liver and skeletal muscle. Aspartate aminotransferase, Human liver comprises two isozymes: the cytoplasmic form (AST1) and the mitochondrial form (AST2). By catalyzing reversible transamination reactions between oxaloacetate, L-glutamate and other substances, it is deeply involved in key physiological processes such as amino acid metabolism, the tricarboxylic acid cycle and neurotransmitter synthesis. Aspartate aminotransferase, Human liver also provides substrate support for the synthesis of urea and purines/pyrimidines. Aspartate aminotransferase, Human liver is a serum marker reflecting cardiac and hepatic injury, and its abnormal levels are also closely associated with myocardial infarction, cardiovascular diseases and various cancers .

HY-16121

CAA-0225	Cathepsin	Others
CAA-0225 is a tissue protease L inhibitor that inhibits rat liver tissue protease L with a IC₅₀ value of 1.9 nM. CAA-0225 can participate in the degradation of autophagosome membrane markers LC3-II and GABARAP (HY-P72639), improve cardiac function in mice with reperfusion injury, and kill and eliminate Trypanosoma brucei parasites ^[1][2][3].

HY-A0114

Moexiprilat RS 10029	Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
Moexiprilat is an inhibitor of angiotensin-converting enzyme (ACE; IC₅₀=2.1 nM) and an active metabolite of the prodrug Moexipril (HY-117281). It is formed from moexipril in vivo by side chain ester hydrolysis. Moexiprilat (10 nM) prevents the estrone- or angiotensin II-stimulated proliferation of primary neonatal rat cardiac fibroblasts. It reduces mean arterial blood pressure and increases the levels of atrial natriuretic peptide, a marker of hypertension, in ovariectomized mice when administered at a dose of 50 mg/kg per day.

HY-138051

TUPS	Cytochrome P450	Cancer
TUPS can inhibit the gene expression of epoxide hydrolase (sEH) and cytochrome P450 (CYP). TUPS can be used in cardiovascular disease-related research .

HY-183057

GRK2 modulator 1	G Protein-coupled Receptor Kinase (GRK) HDAC	Neurological Disease
GRK2 modulator 1 is an orally active, brain-penetrant and selective GRK2 modulator. GRK2 modulator 1 enhances the active, non-phosphorylated GRK2 and prevents mitochondrial GRK2 and TOMM6 aggregation. GRK2 modulator 1 enhances the non-amyloidogenic processing of APP and prevent PHF-tau, neurodegeneration, and neuronal loss. GRK2 modulator 1 decreases the senescence marker, UPAR, reduces the Alzheimer disease (AD)-related mortality, and prolongs survival. GRK2 modulator 1 exerts neuroprotection by inhibiting HDAC6, and counteracts age-related cardiac dysfunction. GRK2 modulator 1 can be used for research on AD .

HY-180583

GRK5-IN-5	G Protein-coupled Receptor Kinase (GRK)	Cardiovascular Disease
GRK5-IN-5 (Compound 4a) is a selective G protein-coupled receptor (GPCR) kinase 5 (GRK5) inhibitor with an IC₅₀ of 0.03 μM. GRK5-IN-5 shows IC₅₀ values of 2.2 and 0.036 μM for GRK2 and GRK6. GRK5-IN-5 has potent anti-myocardial hypertrophy activity and also inhibits the proliferation of non-myocardial cells. GRK5-IN-5 can inhibit the abnormal upregulation of hypertrophy marker genes Nppa and Nppb, thus blocking pathological myocardial remodeling. GRK5-IN-5 can be used for the research of cardiac hypertrophy .

HY-P3016C

Aspartate aminotransferase, Human (HEK293) EC 2.6.1.1, Human (HEK293); GOT, Human (HEK293); AST, Human (HEK293)	Aminotransferases (Transaminases)	Cardiovascular Disease
Aspartate aminotransferase (EC 2.6.1.1), Human (HEK293) is a metabolic regulator with the highest activity in the heart, liver and skeletal muscle. Aspartate aminotransferase, Human (HEK293) comprises two isozymes: the cytoplasmic form (AST1) and the mitochondrial form (AST2). By catalyzing reversible transamination reactions between oxaloacetate, L-glutamate and other substances, it is deeply involved in key physiological processes such as amino acid metabolism, the tricarboxylic acid cycle and neurotransmitter synthesis. Aspartate aminotransferase, Human (HEK293) also provides substrate support for the synthesis of urea and purines/pyrimidines. Aspartate aminotransferase, Human (HEK293) is a serum marker reflecting cardiac and hepatic injury, and its abnormal levels are also closely associated with myocardial infarction, cardiovascular diseases and various cancers .

HY-N19860

L-Balenine	PIN1	Inflammation/Immunology
L-Balenine is an orally active Pin1 inhibitor and intracellular pH buffer. L-Balenine enhances the phagocytic activity of macrophages, and promotes the expression of pro-inflammatory and anti-inflammatory cytokines during muscle degeneration. L-Balenine also upregulates the expression of myogenic marker genes associated with regeneration, thereby effectively driving skeletal muscle regeneration. L-Balenine can be widely used in studies related to skeletal muscle injury and its repair mechanisms .

Cat. No.	Product Name	Target	Research Area